Inhibition of progesterone secretion by oestradiol administered in the luteal phase of assisted conception cycles.
A prospective randomised study was done to assess the effect of supplemental oestradiol in addition to progesterone on the luteal steroid profiles and pregnancy outcome in stimulated cycles with and without pituitary down regulation. Women undergoing stimulated cycle IVF with GnRH-a and FSH (Group A, n = 63) or stimulated intrauterine insemination using CC and FSH (Group B, n = 55) were studied. These subjects were randomly allocated to receive either 400 mg daily of vaginally administrated Cyclogest (progesterone) alone or in combination with 2 mg daily of oral Oestradiol Valerate (E2V) during the luteal phase. Significant lower concentrations of plasma progesterone were observed in those subjects supplemented with both E2V and progesterone compared to those in whom progesterone only was given during the luteal phase (P < 0.05). Exogenous E2V had a minimal impact on plasma oestradiol concentrations and did not disguise the characterised mid luteal decline in oestradiol secretion. The suppressive effect of E2V on plasma progesterone was lost if implantation occurred normally because any small change in steroid concentrations was reversed by the rapidly increasing concentrations of HCG. Similar pregnancy rates were observed among subjects supplemented with or without oestradiol. The addition of oestradiol to the luteal supplement suppresses endogenous corpus luteum progesterone secretion irrespective of the type of assisted conception cycle and that its use is unlikely to be beneficial to the process of implantation.
Tay
P Y
PY
Department of Obstetrics and Gynaecology, University of Malaya, 50603, Kuala Lumpur.
Lenton
E A
EA
D000328:Adult; D003340:Corpus Luteum Maintenance / Q000187:drug effects*; D015536:Down-Regulation; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy*; D010062:Ovulation Induction / Q000379:methods*; D010902:Pituitary Gland / Q000378:metabolism; D011247:Pregnancy; D011256:Pregnancy Outcome; D011374:Progesterone / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D011446:Prospective Studies
D011374:Progesterone; D004958:Estradiol